Table 1.

Risk factors for EBV PTLD in HCT and SOT

Factors which INCREASE the risk of developing EBV PTLD
HCT [3, 10-12, 84-87]	SOT
Anti-thymocyte Globulin (ATG) or alemtuzumab	<12 months after transplant
In vivo T-cell Depletion	Intestine > lung > heart > liver > pancreas > kidney
EBV serology donor/recipient mismatch (recipient-negative/donor-positive)	Donor EBV+/ Recipient EBV−
Cord blood transplantation	Children
Reduced intensity conditioning	Belatacept immunosuppression
HLA mismatch
Splenectomy
Second HSCT
Severe acute or chronic GvHD requiring intensive immunosuppressive therapy
Infusion of mesenchymal stromal cells
Factors which REDUCE the risk of developing EBV PTLD
HCT	SOT
Rituximab exposure within 6 months pre-HSCT	>12 months after transplant
Post-transplant cyclophosphamide (without ATG)	Kidney > pancreas > liver > heart > lung > intestine
Sirolimus use for GVHD Prophylaxis	Recipient EBV+
CD4+ T-lymphocyte count >50 at day +30	Adults